How the Cholesterol Metabolism Pathway Works

Cholesterol metabolism is not a single straight line from mouth to bloodstream. It is a web of interconnected processes in which your body manufactures cholesterol, absorbs it from food, packages it into specialized transport particles, senses how much is present inside each cell, and eliminates the excess through bile. Most of the cholesterol circulating in your blood was made by your own cells, not delivered by your last meal, and the feedback systems controlling production are remarkably sensitive.

What Cholesterol Actually Does in Your Body

Before diving into how cholesterol moves around, it helps to know why the body bothers making so much of it. Cholesterol is a structural component of every cell membrane you have. It wedges between the fatty molecules that form the membrane, adjusting how stiff or fluid the membrane is and influencing which molecules can pass through it.¹ Without the right amount of cholesterol, cell membranes would either be too rigid or too leaky for normal function.

Cholesterol also serves as the starting material for steroid hormones, including cortisol, estrogen, testosterone, and aldosterone. Specialized tissues in the adrenal glands and gonads pull in large quantities of cholesterol specifically for hormone production.² The liver converts cholesterol into bile acids, which are essential for digesting and absorbing dietary fats. And your skin uses a cholesterol-derived molecule as the precursor for vitamin D when exposed to sunlight. So the system exists because cholesterol is genuinely indispensable.

How Your Body Makes Cholesterol

Every nucleated cell in the body can synthesize cholesterol from scratch, but the liver and intestine produce the largest share. The process starts with a two-carbon building block called acetyl-CoA and proceeds through a long chain of enzymatic steps. The rate-limiting enzyme in this chain is HMG-CoA reductase, which sits early in the pathway and acts as a bottleneck. When you hear about statins lowering cholesterol, this enzyme is their target: statins block HMG-CoA reductase, slowing the entire production line.

Textbooks traditionally describe two parallel routes for the later stages of synthesis, named the Bloch pathway and the Kandutsch-Russell pathway. Research using isotope-tracing in mice found something more nuanced: no tissue actually used the traditional Kandutsch-Russell route. Instead, tissues relied on a hybrid version that researchers called the modified Kandutsch-Russell pathway, and the proportion of flux through each route varied wildly by tissue, from under 10% Bloch pathway activity in certain glands to over 95% in the testes.³ The practical upshot is that cholesterol production is not a single uniform process. Different organs tune the pathway differently depending on their needs.

How Dietary Cholesterol Gets Absorbed

When you eat cholesterol-containing food, the cholesterol arrives in your small intestine mixed with bile acids and fats. A protein called NPC1L1, embedded in the membrane of intestinal cells, acts as the primary gateway, pulling cholesterol out of the intestinal contents and into the cell. Research has shown a direct positive link between NPC1L1 expression in the intestine and the amount of cholesterol that ends up in chylomicrons, the lipoprotein particles that carry dietary fat from the gut into the bloodstream.⁴ The drug ezetimibe works by blocking NPC1L1, reducing how much dietary cholesterol the intestine can absorb.

Once inside the intestinal cell, cholesterol needs to be packaged for transport. An enzyme called ACAT2 converts free cholesterol into cholesterol esters, a more compact storage form that packs efficiently into chylomicrons. Mice lacking ACAT2 absorbed only about 16% of cholesterol, compared with roughly 46-47% in normal mice, because their chylomicrons could not carry cholesterol in the esterified form and instead carried it mostly unesterified.⁵ So absorption is not passive diffusion; it requires active transport proteins and intracellular packaging enzymes working in sequence.

The Lipoprotein Shuttle System

Cholesterol does not dissolve in blood. To move it from place to place, the body wraps cholesterol (along with other fats) inside protein-coated particles called lipoproteins. These particles come in several sizes and densities, and each type has a different job.

Chylomicrons carry dietary fat and cholesterol from the intestine to tissues. After delivering most of their cargo, the remnants are taken up by the liver. The liver then repackages cholesterol and fats into VLDL particles and releases them into the bloodstream. As VLDL particles circulate, enzymes called lipoprotein lipase and hepatic lipase strip away their triglycerides, shrinking the particles step by step. This process converts VLDL first into intermediate-density particles (IDL) and eventually into LDL. Interestingly, the conversion is often incomplete: a substantial portion of VLDL mass remains in the VLDL-IDL density range rather than becoming true LDL, and the resulting intermediate particles are larger than LDL with a different lipid ratio.⁶

LDL is what most people think of as “bad cholesterol,” though the particle itself is not intrinsically harmful. Its job is to deliver cholesterol to cells throughout the body. Problems arise when there is more LDL circulating than cells need, allowing particles to linger in the blood and infiltrate artery walls. HDL, the “good cholesterol,” plays a different role that we will come back to shortly.

How Cells Sense and Control Their Own Cholesterol

Each cell monitors its own cholesterol levels with a feedback system that is almost switch-like in its precision. The central players are a family of proteins called SREBPs, which function as master regulators of cholesterol and fat production. SREBPs sit anchored in the membrane of the endoplasmic reticulum, a sprawling internal compartment of the cell. When cholesterol is low, they need to be escorted to another compartment called the Golgi, where they get clipped by two enzymes and released as active transcription factors that switch on genes for cholesterol synthesis and uptake.⁷

The escort that moves SREBPs to the Golgi is a protein called SCAP. SCAP can sense cholesterol directly, and it responds in a remarkably sharp, all-or-nothing fashion. When cholesterol in the ER membrane climbs above about 5% of total ER lipids, SCAP’s transport activity shuts off abruptly. When cholesterol dips below that threshold, transport resumes just as sharply.⁸ This creates a tight thermostat: even small changes in ER cholesterol levels flip the system between “make more” and “stop making.”

There is an additional brake. When sterols are plentiful, anchor proteins called Insig-1 and Insig-2 physically grab the SCAP-SREBP complex and hold it in the ER, preventing the trip to the Golgi entirely.⁹ The result is that cholesterol production and LDL receptor expression are tightly coupled to the cell’s actual needs, rising and falling in tandem with intracellular cholesterol concentrations.

The LDL Receptor and Its Nemesis, PCSK9

When cells need cholesterol from the bloodstream, they display LDL receptors on their surface. These receptors grab passing LDL particles, pull them into the cell through a process called receptor-mediated endocytosis, and then recycle back to the surface to grab more.¹⁰ A single LDL receptor can make this round trip hundreds of times before it wears out, which makes the system highly efficient at clearing LDL from the blood.

But the body also has a mechanism for limiting how many LDL receptors survive. A protein called PCSK9, produced mainly by the liver, binds to LDL receptors on the cell surface and tags them for destruction. When PCSK9 attaches to a receptor, the receptor gets dragged into the cell and routed to lysosomes for breakdown instead of being recycled.¹¹ Another protein called IDOL can also direct LDL receptors toward degradation, and the balance between receptor recycling and these degradation pathways determines how effectively the liver clears LDL cholesterol from circulation.¹²

This is why PCSK9 became such a high-profile drug target. People with naturally occurring mutations that boost PCSK9 activity end up with high LDL and early heart disease, while people with loss-of-function mutations have unusually low LDL and much less cardiovascular risk.¹³ PCSK9 inhibitor drugs, now widely used, work by blocking this receptor-destruction process, allowing more LDL receptors to keep recycling and pulling LDL out of the blood.

Getting Cholesterol Out of Lysosomes

Once an LDL particle has been swallowed by the cell through receptor-mediated endocytosis, it ends up in a lysosome, where enzymes break it apart and release free cholesterol. But cholesterol cannot simply float out of the lysosome on its own. Two proteins cooperate to export it. NPC2, a small soluble protein inside the lysosome, picks up the cholesterol and hands it off to NPC1, a larger protein embedded in the lysosomal membrane. Structural studies have revealed a direct tunnel between the two proteins’ cholesterol-binding pockets, supporting a “hydrophobic hand-off” model where cholesterol slides from one protein to the other without ever being exposed to the watery interior of the lysosome.¹⁴

When either NPC1 or NPC2 is defective, cholesterol accumulates inside lysosomes and cannot reach the rest of the cell. This is the cause of Niemann-Pick type C disease, a rare genetic condition in which cholesterol and other lipids build up in cells throughout the body, damaging the liver, spleen, and brain. The lysosomal export step, often overlooked in simple descriptions of cholesterol metabolism, turns out to be a critical bottleneck.

Intracellular Storage and the Role of ACAT

Once freed from the lysosome, cholesterol faces a choice. Some goes to the cell membrane. Some travels to the ER, where it can regulate the SCAP-SREBP feedback system described earlier. And some gets stored. Free cholesterol is actually toxic to cells at high concentrations, so cells protect themselves by converting excess free cholesterol into cholesterol esters using an enzyme called ACAT, which sits in the ER membrane.¹⁵ ACAT attaches a fatty acid chain to the cholesterol molecule, creating a cholesterol ester that gets packed into lipid droplets for safe storage.¹⁶

Mammals have two forms of the enzyme. ACAT1 operates in most cell types and handles intracellular storage. ACAT2, as discussed earlier, is concentrated in the intestine and liver, where it packages cholesterol esters into lipoproteins for export. This division of labor means that cholesterol esterification serves two entirely different purposes depending on where in the body it happens.

Reverse Cholesterol Transport

If the forward pathway moves cholesterol from the liver and gut out to body tissues, reverse cholesterol transport is the return trip. It is the process by which excess cholesterol in peripheral tissues gets ferried back to the liver for disposal. HDL particles are the key carriers.¹⁷

The process begins at the cell surface. A transporter called ABCA1 actively pumps cholesterol out of cells onto lipid-poor apoA-I proteins, the main protein component of HDL. Research on human macrophages found that ABCA1 is the sole transporter responsible for the cholesterol efflux that happens when a nuclear receptor called LXR is activated. Another transporter, ABCG1, was strongly upregulated in the same conditions, but silencing it did not reduce cholesterol efflux to HDL at all, and the process was abolished entirely in cells from patients with Tangier disease, who lack functional ABCA1.¹⁸ This ATP-dependent export step is particularly important in macrophages within artery walls: if cholesterol cannot get out, macrophages become bloated foam cells, driving the formation of atherosclerotic plaques.

Once loaded with cholesterol, HDL particles circulate to the liver, where the cholesterol can be taken up and either reused or converted into bile acids for excretion.

Bile Acids and the Final Exit

The liver is the only organ that can permanently remove cholesterol from the body, and it does so in two ways. First, it converts cholesterol into bile acids through a multi-step enzymatic process. Second, it secretes cholesterol directly into bile. Both routes deliver cholesterol and its derivatives into the intestine, where some is reabsorbed and the rest leaves the body in stool.¹⁹

Bile acid synthesis is actually a major regulatory node. The bile acid pool in the intestine signals back to the liver through a receptor called FXR, which adjusts both bile acid production and cholesterol metabolism. Drugs called bile acid sequestrants exploit this loop by binding bile acids in the gut and preventing their reabsorption. When less bile acid returns to the liver, the liver ramps up conversion of cholesterol to bile acids, effectively pulling cholesterol out of circulation. The recycling between liver and intestine, known as enterohepatic circulation, handles the turnover of bile acids multiple times per day.

Cholesterol in the Brain

The brain contains roughly a quarter of the body’s total cholesterol, yet it operates as an almost completely independent system. The blood-brain barrier prevents lipoproteins from crossing in or out, so brain cells cannot rely on LDL delivery or HDL-mediated export the way the rest of the body does.²⁰ Instead, astrocytes manufacture cholesterol locally and supply it to neurons, which need it for synaptic function and membrane maintenance but produce less on their own.

To get rid of excess cholesterol, brain cells convert it to a more polar molecule called 24S-hydroxycholesterol, which can cross the blood-brain barrier and enter the general circulation for hepatic disposal. Disruptions to this isolated system are linked to neurodegenerative conditions. Niemann-Pick type C disease, for instance, causes severe neurological damage partly because cholesterol accumulates in brain lysosomes when the NPC1/NPC2 handoff fails.

When Genetic Mutations Disrupt the System

Familial hypercholesterolemia is the best-known genetic disorder of cholesterol metabolism. It is caused by mutations in genes encoding the LDL receptor, apolipoprotein B (the protein on LDL that the receptor grabs), or PCSK9. Thousands of such variants have been catalogued.²¹ People who inherit one defective copy have elevated LDL from birth and face a substantially higher risk of premature heart disease. Those who inherit two defective copies can have LDL levels several times above normal and may develop heart attacks in childhood without treatment.

Familial hypercholesterolemia is sometimes described as rare, but heterozygous forms likely affect roughly one in 250 people, making it one of the most common serious genetic conditions worldwide. It often goes undiagnosed because standard cholesterol screening does not distinguish genetic from lifestyle-driven elevations. Recognizing it matters because affected individuals typically need medication early in life and standard dietary advice alone is insufficient to control their LDL levels.

How Drugs Target Different Parts of the Pathway

Each class of cholesterol-lowering drug intervenes at a different point in the metabolic pathway. Statins inhibit HMG-CoA reductase, cutting cholesterol production in the liver. The liver compensates by making more LDL receptors, which pulls LDL out of the blood faster. Ezetimibe blocks NPC1L1 in the intestine, reducing cholesterol absorption. Bile acid sequestrants trap bile acids and force the liver to convert more cholesterol into replacement bile acids. PCSK9 inhibitors prevent LDL receptor degradation, keeping more receptors active on liver cells. Newer RNA-based therapies like inclisiran silence PCSK9 production at the genetic level rather than blocking the protein after it is made.

These drugs can be combined because they attack separate steps. Lowering LDL by about 1 mmol/L through any of these mechanisms is associated with roughly a 22-23% reduction in cardiovascular risk, regardless of which drug achieves it.²² The benefit tracks with how much LDL goes down, not with how you bring it down, which reinforces that LDL itself is the driver of arterial damage.

An Ancient Pathway

Sterol biosynthesis is far older than animals. Molecular clock analyses tracing the evolutionary history of sterol-making genes suggest that simple sterol biosynthesis existed around 2.31 billion years ago, roughly coinciding with the Great Oxidation Event, when molecular oxygen first became widely available in the atmosphere and oceans.²³ Oxygen is required for several steps in the cholesterol synthesis pathway, which may explain why sterol production became possible only after atmospheric chemistry changed. Bacteria and early eukaryotes appear to have shared sterol biosynthesis genes through horizontal gene transfer, and the pathway was already in place more than a billion years before the oldest sterane biomarkers detected in the fossil record. The elaborate cholesterol metabolism system in modern mammals is a deeply conserved piece of biochemistry, refined over eons but rooted in some of the earliest chemical innovations of life on an oxygenated planet.